PeptiMed's Unattributed Round

PeptiMed raised a round of funding on June 23, 2016.

PeptiMed has invented a proprietary siRNA therapeutic drug that targets the EVI1 gene, called siEVI1, for treatment of advanced breast, prostate, lung, colon, ovarian, and skin cancer. The drug may be…

Articles about PeptiMed's Unattributed Round: